Lusutrombopag (Mulpleta)

Wenkeda® is the latest generation of oral small molecule thrombopoietin receptor agonist (TPO-RA), which acts on the transmembrane domain of human thrombopoietin (TPO) receptor, activates the signal transduction pathway in the same way as endogenous TPO, and promotes platelet production. Wenkeda® has good safety, does not require injection and dose titration, is easy to use, and has stable efficacy, is not affected by drug interactions, and is not affected by food status. It provides patients with a better medical option and may bring about treatment changes in the field of chronic liver disease with thrombocytopenia.